 random studi cisplatin versu cisplatin vindesin non-smal cell lung carcinoma between august march random studi cisplatin cddp day cddp vindesin vd day consecut patient inoper non-smal cell lung cancer nsclc complet respons respons rate cddp vd patient cddp patient differ median durat respons week cddp vd week cddp median surviv time week cddp vd week cddp signific differ toxic arm myelosuppress alopecia peripher neuropathi cddp vd lethal episod hepatoren syndrom cddp vd arm variabl eastern cooper oncolog group ecog perform statu PS age sex stage weight loss serum lactat dehydrogenas ldh level albumin level histolog cell type chemotherapi arm chemotherapi arm signific factor major respons multipl logist regress analysi signific predictor surviv PS sex stage cox proport hazard model PS femal sex stage surviv respons rate combin arm singl agent arm surviv benefit patient combin chemotherapi effect chemotherapi regimen